Prior authorization for FDA-approved PARP inhibitors in ovarian cancer

• প্রধান লেখক: Anna Jo Bodurtha Smith (লেখক), Annie Apple (লেখক), Audra Hugo (লেখক), Ashley Haggerty (লেখক), Emily M. Ko (লেখক)
• বিন্যাস: গ্রন্থ
• প্রকাশিত: Elsevier, 2024-04-01T00:00:00Z.
• বিষয়গুলি: article
• অনলাইন ব্যবহার করুন: Connect to this object online.

Objectives: PARP inhibitors (PARP-I) improve survival in ovarian cancer, especially in patients with germline or somatic BRCA mutations or other homologous recombination deficiency (HRD). With high efficacy and costs, insurers may enact barriers or facilitators to PARP-I. Our objective was to examin...